Phyllis A Gimotty1, DuPont Guerry. 1. Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia, 19104-6021, USA. pgimotty@upenn.edu
Abstract
CONTEXT: While most patients diagnosed with thin cutaneous melanoma will have a good prognosis, nearly 5% will die of their disease. Thin melanomas are common and approximately one-quarter of all melanoma-related deaths result from thin primary tumors. Patients with thin melanoma commonly have sentinel lymph node biopsies that are uncommonly positive. OBJECTIVE: To review the progress that has been made in the translation of prognostic and predictive biomarkers for patients with thin melanomas by focusing on the developments during the last 5 years in using measures of tumor proliferation. Given the paucity of biomarkers for patients with thin melanoma, we review some of the challenges in the development, validation, and translation of new biomarkers into clinical practice. DATA SOURCES: Surveillance, Epidemiology and End Results registry data, cohort data from a cancer center's program in melanoma, and focused literature review. CONCLUSIONS: The presence of dermal mitoses improves prognostication and prediction. To optimize patient management, biomarkers reflecting biologic processes underlying tumor progression will need to be included in panels and risk models, validated, generalized, and ratified.
CONTEXT: While most patients diagnosed with thin cutaneous melanoma will have a good prognosis, nearly 5% will die of their disease. Thin melanomas are common and approximately one-quarter of all melanoma-related deaths result from thin primary tumors. Patients with thin melanoma commonly have sentinel lymph node biopsies that are uncommonly positive. OBJECTIVE: To review the progress that has been made in the translation of prognostic and predictive biomarkers for patients with thin melanomas by focusing on the developments during the last 5 years in using measures of tumor proliferation. Given the paucity of biomarkers for patients with thin melanoma, we review some of the challenges in the development, validation, and translation of new biomarkers into clinical practice. DATA SOURCES: Surveillance, Epidemiology and End Results registry data, cohort data from a cancer center's program in melanoma, and focused literature review. CONCLUSIONS: The presence of dermal mitoses improves prognostication and prediction. To optimize patient management, biomarkers reflecting biologic processes underlying tumor progression will need to be included in panels and risk models, validated, generalized, and ratified.
Authors: K M Joyce; N M McInerney; C W Joyce; D M Jones; A J Hussey; P Donnellan; M J Kerin; J L Kelly; P J Regan Journal: Ir J Med Sci Date: 2014-11-01 Impact factor: 1.568
Authors: Phyllis A Gimotty; Ronald Shore; Nancy L Lozon; Jeanne Whitlock; Sidan He; Fawn D Vigneau; Lois Dickie; David E Elder; Xiaowei Xu; Ann G Schwartz; DuPont Guerry Journal: J Invest Dermatol Date: 2016-06-25 Impact factor: 8.551
Authors: Jacob S Ankeny; Brian Labadie; Jason Luke; Eddy Hsueh; Jane Messina; Jonathan S Zager Journal: Clin Exp Metastasis Date: 2018-05-02 Impact factor: 5.150
Authors: Hollis Viray; William R Bradley; Kurt A Schalper; David L Rimm; Bonnie E Gould Rothberg Journal: Arch Pathol Lab Med Date: 2013-08 Impact factor: 5.534
Authors: Bonnie E Gould Rothberg; Kaleigh J Bulloch; Judith A Fine; Raymond L Barnhill; Marianne Berwick Journal: Cancer Epidemiol Date: 2014-09-05 Impact factor: 2.984
Authors: Björn Nodin; Marie Fridberg; Liv Jonsson; Julia Bergman; Mathias Uhlén; Karin Jirström Journal: Diagn Pathol Date: 2012-07-17 Impact factor: 2.644